Floortje J Backes, MD
Academic Title: Professor in the College of Medicine
Research Program: Cancer Control
About Me
More info forI am a board-certified gynecologic oncologist and a tenured professor at The Ohio State University Wexner Medical Center and the OSUCCC – James. I specialize in taking care of patients with ovarian, endometrial, uterine, cervical, vaginal, vulva, and other rare gynecologic cancers. My expertise includes performing radical tumor reductive surgery, offering minimally invasive surgical procedures such as laparoscopy and robotics, and administering chemotherapy. I also serve as vice chair of the Cancer Institutional Review Board at The James. I am committed to providing the best care for my patients through comprehensive clinical care, and by offering the most advanced therapies available. I am honored to have been rated in the top 10 percent of physicians in the nation for patient satisfaction and have been named to the Castle Connolly list of “Top Doctors” and "Best Doctors in America.” In addition to my clinical responsibilities, I am the director of research for the Division of Gynecologic Oncology, and I manage the research portfolio for the Disease Specific Research Group. My current work focuses on novel treatments for gynecologic cancers, identifying predictors and biomarkers of cancer outcomes, and examining sentinel lymph nodes in endometrial cancer. I have extensive experience leading clinical trials both here at Ohio State and nationally. My role includes developing and collaborating on clinical trials and engaging in translational research to offer improved and novel treatments for gynecologic cancers. My research has been published in prestigious peer-reviewed journals including Gynecologic Oncology, Journal of Clinical Oncology, Cancer, and the Journal of Surgical Oncology. I am also on multiple national committees including the Society of Gynecologic Oncology, NRG Oncology, and the International Gynecologic Cancer Society. I enjoy working within a highly experienced, multidisciplinary team at The James. Together, we provide tailored, individualized treatment plans for our patients, utilizing a variety of clinical trials and resources to ensure the best possible outcomes.
Clinical Expertise
More info for- Cervical Cancer
- Gynecologic Cancers
- Reproductive Health
- Women's Health
- Vaginal Cancers
- Endometrial Cancers
- Ovarian Cancers
- Vulvar Cancers
- Uterine Cancers
- Minimally Invasive Surgical Procedures
- Robotics
- Peritoneal Cancers
Research Interests
More info for- Obesity
- Colorectal Neoplasms
- Body Mass Index
- Uterine Neoplasms
- Neoplasms
- Neutropenia
- Endometrial Neoplasms
- Uterine Cervical Neoplasms
- Ovarian Neoplasms
- Colorectal Neoplasms, Hereditary Nonpolyposis
Where I See Patients
More info forThe Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
460 W. 10th Ave. Columbus, Ohio 43210 800-293-5066 Location InformationEducation & Training
More info forFellowship - Gynecologic Oncology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Internship - Obstetrics & Gynecology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Residency - Obstetrics & Gynecology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Medical School
- Rijksuniversiteit Groningen
9712 CP, Groningen
- Ohio State University Wexner Medical Center
Academic Office & Contact Information
More info forAcademic Office:
Starling Loving Hall
320 W 10th Ave
Columbus, Ohio 43210-1280Phone:
614-293-9337Email:
backes.11@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forOctober 16, 2024Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.
Slomovitz BM, Cibula D, Lv W, Ortaç F, Hietanen S, Backes F, Kikuchi A, Lorusso D, Danska-Bidzinska A, Samouëlian V, Barretina-Ginesta MP, Vulsteke C, Lai CH, Pothuri B, Zhang Y, Magallanes-Maciel M, Amit A, Guarneri V, Zagouri F, Bell M, Welz J, Eminowicz G, Hruda M, J Willmott L, Lichfield J, Wang W, Orlowski R, Aktan G, Gladieff L, Van Gorp T
J Clin Oncol
October 1, 2024Non-surgical management of recurrent Paget's disease of the vulva: A case report.
Coffey-Noriega E, Kennedy H, Backes FJ
Gynecol Oncol Rep
October 1, 2024NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.
Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, Martin L, Matei D, Miller DS, Robertson S, Barroilhet L, Uppal S, Hendrickson AW, Gershenson DM, Gray HJ, Hakam A, Jain A, Konecny GE, Moroney J, Ratner E, Schorge J, Thaker PH, Werner TL, Zsiros E, Behbakht K, Chen LM, DeRosa M, Eisenhauer EL, Leiserowitz G, Litkouhi B, McHale M, Percac-Lima S, Rodabaugh K, Vargas R, Jones F, Kovach E, Hang L, Ramakrishnan S, Alvarez RD, Armstrong DK
J Natl Compr Canc Netw
September 11, 2024Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
Brown J, Miller A, Holman LL, Backes F, Nagel C, Bender D, Miller DS, Powell MA, Westin SN, Bonebrake A, Muller CY, Secord AA, Crane E, Schorge J, Tew WP, Sood AK, Bookman MA, Aghajanian C, Gershenson DM
Gynecol Oncol
August 23, 2024ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer.
Van Gorp T, Cibula D, Lv W, Backes F, Ortaç F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L, Barretina-Ginesta MP, Gilbert L, Pothuri B, Chen X, Flores MB, Levy T, Colombo N, Papadimitriou C, Buchanan T, Hanker LC, Eminowicz G, Rob L, Black D, Lichfield J, Lin G, Orlowski R, Keefe S, Lortholary A, Slomovitz B, ENGOT-en11/GOG-3053/KEYNOTE-B21 investigators
Ann Oncol
July 31, 2024Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer.
O'Malley DM, Myers T, Wimberger P, Gorp TV, Redondo A, Cibula D, Nicum S, Rodrigues M, Backes FJ, Barlin JN, Lewin SN, Lim P, Pothuri B, Diver E, Banerjee S, Lorusso D
Future Oncol
June 28, 2024Associations between race and ethnicity and treatment setting among gynecologic cancer patients.
Meade CE, Sinnott JA, Backes FJ, Cosgrove CM, Quick AM, Trabert B, Plascak JJ, Felix AS
Gynecol Oncol
April 25, 2024Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-Oncology Research.
Chambers L, Haight P, Chalif J, Mehra Y, Spakowicz D, Backes FJ, Cosgrove CM, O'Malley DM, Vargas R, Corr BR, Bae-Jump VL, Arend RC
Clin Cancer Res
April 25, 2024Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial.
Klopp AH, Enserro D, Powell M, Randall M, Schink JC, Mannel RS, Holman L, Bender D, Kushnir CL, Backes F, Zweizig SL, Waggoner S, Bradley KA, Lawrence LD, Hanjani P, Darus CJ, Small W, Cardenes HR, Feddock JM, Miller DS
J Clin Oncol
April 10, 2024Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
Gien LT, Enserro DM, Block MS, Waggoner S, Duska LR, Wahner-Hendrickson AE, Thaker PH, Backes F, Kidd M, Muller CY, DiSilvestro PA, Covens A, Gershenson DM, Moore KN, Aghajanian C, Coleman RL
Gynecol Oncol
April 1, 2024Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84].
Riedinger CJ, Barrington DA, Nagel CI, Khadraoui WK, Haight PJ, Tubbs C, Backes FJ, Cohn DE, O'Malley DM, Copeland LJ, Chambers LM
Gynecol Oncol
March 29, 2024Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer.
Riedinger CJ, Barrington DA, Nagel CI, Khadraoui WK, Haight PJ, Tubbs C, Backes FJ, Cohn DE, O'Malley DM, Copeland LJ, Chambers LM
Gynecol Oncol
March 19, 2024Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ
Future Oncol
January 22, 2024Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Levine MD, Wang H, Sriram B, Khan A, Senter L, McLaughlin EM, Bixel KL, Chambers LM, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Backes FJ
Gynecol Oncol
December 21, 2023NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
Rimel BJ, Enserro D, Bender DP, Jackson CG, Tan A, Alluri N, Borowsky M, Moroney J, Hendrickson AW, Backes F, Swisher E, Powell M, MacKay H
Cancer
December 4, 2023Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma.
Barlin JN, Mahar B, Ata A, Cormier B, Michelin D, Salani R, Backes F, Levinson K, Cantrell LA, Weinberg L, Wagreich A, Savage D, Gasson C, Denniston K, Martin J, McElrath T, Timmins PF
Gynecol Oncol
December 1, 2023Racial and Ethnic Disparities in Clinical Trial Enrollment Among Women With Gynecologic Cancer.
Khadraoui W, Meade CE, Backes FJ, Felix AS
JAMA Netw Open
September 21, 2023The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer.
Haight PJ, Kistenfeger Q, Riedinger CJ, Khadraoui W, Backes FJ, Bixel KL, Copeland LJ, Cohn DE, Cosgrove CM, O'Malley DM, Nagel CI, Spakowicz DJ, Chambers LM
Gynecol Oncol
July 1, 2023Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Praiss AM, Miller A, Smith J, Lichtman SM, Bookman M, Aghajanian C, Sabbatini P, Backes F, Cohn DE, Argenta P, Friedlander M, Goodheart MJ, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray H, Secord AA, Van Le L, O'Cearbhaill RE
Gynecol Oncol
June 15, 2023"More than a song and dance": Exploration of patient perspectives and educational quality of gynecologic cancer content on TikTok.
Morton M, Haight PJ, Khadraoui W, Backes F, Bixel K, O'Malley DM, Nagel C, Chambers LM
Gynecol Oncol
April 8, 2023Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes.
Levine MD, Barrington DA, Meade CE, Lammers SM, McLaughlin EM, Suarez AA, Backes FJ, Copeland LJ, O'Malley DM, Cosgrove CM, Cohn DE, Nagel CI, Felix AS, Bixel KL
Gynecol Oncol
April 1, 2023Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer.
Piver RN, Wagner VM, Levine MD, Backes FJ, Chambers LJ, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Bixel KL
Gynecol Oncol Rep
April 1, 2023Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series.
Calo CA, Levine MD, Brown MD, O'Malley DM, Backes FJ
Gynecol Oncol Rep
April 1, 2023Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
Levine MD, O'Malley DM, Haight PJ, Senter L, Wagner V, Bixel KL, Cohn DE, Copeland LJ, Cosgrove CM, McLaughlin EM, Backes FJ
Gynecol Oncol Rep
March 27, 2023Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath Iii CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C
N Engl J Med
March 16, 2023Do Not Forget about Hormonal Therapy for Recurrent Endometrial Cancer: A Review of Options, Updates, and New Combinations.
Wagner VM, Backes FJ
Cancers (Basel)
January 1, 2023Epigenetic MMR defect identifies a risk group not accounted for through traditional risk stratification algorithms in endometrial cancer.
Riedinger CJ, Brown M, Haight PJ, Backes FJ, Cohn DE, Goodfellow PJ, Cosgrove CM
Front Oncol
December 24, 2022Postoperative Venous Thromboembolism Risk Stratification in Patients with Uterine Cancer.
Wagner VM, Piver RN, Levine MD, Backes FJ, Chambers LJ, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Bixel KL
Am J Obstet Gynecol
September 22, 2022The contemporary presentation and diagnosis of endometrial cancer recurrence: When, where, and how?
Riedinger CJ, Patterson JM, Backes FJ, O'Malley D, Bixel KL, Copeland LJ, Cohn DE, Goodfellow PJ, Cosgrove CM
Gynecol Oncol
September 1, 2022NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath Iii CA, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L
J Natl Compr Canc Netw
September 1, 2022Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
Chase DM, Marín MR, Backes F, Han S, Graybill W, Mirza MR, Pothuri B, Mangili G, O'Malley DM, Berton D, Willmott L, Baumann K, Coleman RL, Safra T, Heinzelmann-Schwarz V, Lorusso D, Karl FM, Woodward T, Monk BJ, Gonzalez-Martin A, PRIMA/ENGOT-OV26/GOG-3012 Investigators
Gynecol Oncol
August 23, 2022Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study.
Casablanca Y, Wang G, Lankes HA, Tian C, Bateman NW, Miller CR, Chappell NP, Havrilesky LJ, Wallace AH, Ramirez NC, Miller DS, Oliver J, Mitchell D, Litzi T, Blanton BE, Lowery WJ, Risinger JI, Hamilton CA, Phippen NT, Conrads TP, Mutch D, Moxley K, Lee RB, Backes F, Birrer MJ, Darcy KM, Maxwell GL
Cancers (Basel)
August 2, 2022Less is more: Clinical utility of postoperative labs following minimally invasive hysterectomy for endometrial cancer.
Lightfoot MDS, Felix AS, Calo CA, Hosmer-Quint JT, Taylor KL, Brown MB, Salani R, Copeland LJ, O'Malley DM, Bixel KL, Cohn DE, Fowler JM, Backes FJ, Cosgrove CM
Am J Obstet Gynecol
August 1, 2022High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors.
Calo CA, Barrington DA, Brown M, Gonzalez L, Baek J, Huffman A, Benedict J, Backes F, Chambers L, Cohn D, Copeland L, Cosgrove C, Nagel C, O'Malley D, Bixel K
Gynecol Oncol Rep
July 11, 2022What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.
Pitiyarachchi O, Friedlander M, Java JJ, Chan JK, Armstrong DK, Markman M, Herzog TJ, Monk BJ, Backes F, Secord AA, Bonebrake A, Rose PG, Tewari KS, Lentz SS, Geller MA, Copeland LJ, Mannel RS
Gynecol Oncol
May 6, 2022A Novel Estrogen Receptor β Agonist Diminishes Ovarian Cancer Stem Cells via Suppressing the Epithelial-to-Mesenchymal Transition.
Banerjee A, Cai S, Xie G, Li N, Bai X, Lavudi K, Wang K, Zhang X, Zhang J, Patnaik S, Backes FJ, Bennett C, Wang QE
Cancers (Basel)
March 1, 2022Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
Lheureux S, Matei DE, Konstantinopoulos PA, Wang BX, Gadalla R, Block MS, Jewell A, Gaillard SL, McHale M, McCourt C, Temkin S, Girda E, Backes FJ, Werner TL, Duska L, Kehoe S, Colombo I, Wang L, Li X, Wildman R, Soleimani S, Lien S, Wright J, Pugh T, Ohashi PS, Brooks DG, Fleming GF
J Immunother Cancer
November 1, 2021Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy.
Graves SM, Backes FJ
Gynecol Oncol Rep
November 1, 2021Wound complications following vulvar excision for nonmalignant lesions.
Boyles GP, Weaver AM, Cohn DE, Backes FJ, Copeland LJ, Bixel KL, Fowler JM, O'Malley DM, Cosgrove CM
AJOG Glob Rep
August 17, 2021Endometrial Cancer: Who lives, who dies, can we improve their story?
Cosgrove CM, Backes FJ, O'Malley D, Bixel KL, Suarez AA, Fowler JM, Copeland LJ, Goodfellow PJ, Cohn DE
Oncologist
July 13, 2021Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Backes FJ, Wei L, Chen M, Hill K, Dzwigalski K, Poi M, Phelps M, Salani R, Copeland LJ, Fowler JM, Cohn DE, Bixel K, Cosgrove C, Hays J, O'Malley D
Gynecol Oncol
May 3, 2021Impact of Molecular Classification on Treatment Paradigms in Uterine Cancers.
Cosgrove CM, Barrington D, Backes FJ
Curr Oncol Rep
March 4, 2021Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
Backes FJ, Felix AS, Plante M, Grégoire J, Sullivan SA, Rossi EC, Tanner EJ, Stewart KI, Soliman PT, Holloway RW, Abu-Rustum NR, Leitao MM
Gynecol Oncol
January 27, 2021Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations.
Hamilton CA, Pothuri B, Arend RC, Backes FJ, Gehrig PA, Soliman PT, Thompson JS, Urban RR, Burke WM
Gynecol Oncol
January 12, 2021Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II.
Hamilton CA, Pothuri B, Arend RC, Backes FJ, Gehrig PA, Soliman PT, Thompson JS, Urban RR, Burke WM
Gynecol Oncol
January 1, 2021Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.
Hampel H, Pearlman R, de la Chapelle A, Pritchard CC, Zhao W, Jones D, Yilmaz A, Chen W, Frankel WL, Suarez AA, Cosgrove C, Backes F, Copeland L, Fowler J, O'Malley D, Salani R, McElroy JP, Stanich PP, Goodfellow P, Cohn DE
Gynecol Oncol
September 1, 2020Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.
Barrington DA, Felix AS, Owda R, Suarez AA, Cohen DW, Senter L, Copeland LJ, Fowler JM, Backes FJ, Cohn DE, Bixel KL, O'Malley DM, Salani R, Cosgrove CM
Surg Oncol
August 17, 2020Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma.
Koivisto CS, Parrish M, Bonala SB, Ngoi S, Torres A, Gallagher J, Sanchez-Hodge R, Zeinner V, Nahhas GJ, Liu B, Cohn DE, Backes FJ, Goodfellow PJ, Chamberlin HM, Leone G
Neoplasia
June 29, 2020Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD
Clin Cancer Res
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Backes has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- AstraZeneca
- Eisai, Inc.
- EMD Serono, Inc.
- GlaxoSmithKline
- Onclive
- Research to Practice
- UpToDate
- Creative Educational Concepts, Inc
- Daiichi Sankyo
- Immunogen, Inc.
- Society of Gynecologic Oncology
- Curio Science LLC
- BioNTech SE
- Merck Sharp & Dohme
Patient Comments
I saw them all each visit.I couldn't ask for more.!!!!
Dr, Backes was very professional she is fantastic
Dr. Bakus spends a tremendous amount of time explaining my cancer. She never seems to rush. I am very grateful
I love Dr Backes and her staff!
Dr. Backes has been terrific.
This Staff is very caring with their patients
Dr. Backes and her staff are caring and considerate.
On August 6th everyone was great.
Dr. Backes is always very informative and educational, I've learned so much about my cancer, my body, treatments and care. She is also very good about asking me if I'm understanding what she's telling me and if I have any questions or concerns.
Dr.Backus and her staff are a step above any specialist I have ever been to period.
I spent a lot of time with the resident and medical student, both of whom were very thorough and empathetic. Comparatively I did not have much time with the attending physician and she seemed somewhat annoyed by the questions that I had.
Dr Backes and her nurse Tammy are awesome.
Very professional
Dr Backes and staff very comforting
Very good
I couldn't find a better group of people to take care of me. All of my questions are answered and they don't hesitate to give me answers to anything I ask.
Dr. Backes was attentive to all my concerns and questions and gave concise and compassionate answers.
I wish the ratings went beyond very good. I would have liked to have been able to select EXCELLENT in this area of the survey.
Dr Backes is incredible.
Dr Backes' expertise is very much appreciated
Impressed
I am very grateful to be under the care of Dr. Backus, she is very knowledgeable, understanding, and willing to provide options and answer all of my questions. She never appears to be in a rush ( it seems as if I am her only patient) as she wants to make certain all of my questions and concerns are answered before leaving.
Doctor discussed findings and suggested treatment, to which I agreed.
Dr Backes is the best.
Everyone I came into contact with were very professional and knowledgeable.
DR Backus and her assistant were very good. They explained things very well.
Again my training and education. They answer all my questions, my follow-up questions, and they keep me informed at all times what the next step will be
I found Dr. Backes to be very engaged and caring regarding my diagnosis and treatment. I saw her for a second opinion regarding my condition and current treatment. She was very well prepared regarding my current condition and treatment, and forthcoming regarding her thoughts about how my treatment should proceed.
Dr. Backes and her staff are outstanding.
The physician seemed hurried & basically typed instead of talking directly to me. I repeated what I heard, but she didn't seem to really answer my concerns. The PA had done a nice job & took her time.